Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease

NCT05083364 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

C3 Glomerulopathy
IgA Nephropathy

Interventions

DRUG: ARO-C3
DRUG: Placebo

Sponsor

Arrowhead Pharmaceuticals